GENinCode has announced FY25 results to December 2025, reporting revenue of £3.1m, up 14% YoY, gross profit of £1.8m and an adjusted EBITDA loss of £4.9m. Revenue growth was driven by a strong performance from the largest established market, Spain. During FY25 and post-year end period, GENinCode agreed a partnership with Thermo Fisher for the distribution and sale of CARDIO inCode Score in the US and EMEA regions, significantly increased the number of US institutions onboarded to use the company ....
